Poziotinib
CAS 1092364-38-9 2 FDA-DMF suppliersSmall Molecule
Overview
Poziotinib is a potent, orally active quinazoline-based pan-HER inhibitor targeting multiple domains within the HER family. It is primarily in development for the treatment of non-small cell lung cancer with EGFR exon 20 insertions.
Therapeutic areas
OncologyNon-Small Cell Lung Cancer
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.